医学
临床终点
安慰剂
内科学
放化疗
肿瘤科
头颈部鳞状细胞癌
头颈部癌
放射治疗
顺铂
临床研究阶段
癌症
化疗
随机对照试验
外科
病理
替代医学
作者
Jean Bourhis,Barbara Burtness,Lisa Licitra,Christopher M. Nutting,Jonathan D. Schoenfeld,Mokhtar Omar,Florilène Bouisset,Heidi Nauwelaerts,Yulia Urfer,Claudio Zanna,Ezra E.W. Cohen
出处
期刊:Future Oncology
[Future Medicine]
日期:2022-05-01
卷期号:18 (14): 1669-1678
被引量:14
标识
DOI:10.2217/fon-2021-1634
摘要
Xevinapant is a first-in-class antagonist of inhibitor of apoptosis proteins, which enhances cancer cell sensitivity to chemotherapy and radiotherapy. In a phase II randomized study in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN), xevinapant plus standard-of-care cisplatin-based chemoradiotherapy (CRT) showed superior efficacy versus placebo plus CRT. Here, we describe the design of TrilynX (NCT04459715), a randomized, double-blind, phase III study. In total, 700 patients with unresected LA SCCHN will be randomized 1:1 to receive xevinapant or placebo plus standard-of-care CRT followed by xevinapant monotherapy or placebo. The primary end point is event-free survival by blinded independent review committee. Secondary end points include progression-free survival, locoregional control, overall survival and safety.Xevinapant is being developed as a new type of cancer treatment. Xevinapant works by enhancing the effects of chemotherapy and radiotherapy (chemoradiotherapy), which are standard anticancer treatments. Researchers are studying whether adding xevinapant to these treatments could be helpful for people with head and neck cancers that have not spread to other parts of the body and cannot be removed by surgery. In a study of 96 people with this disease, those treated with chemoradiotherapy plus xevinapant on average lived longer than people treated with chemoradiotherapy plus placebo (liquid that looked the same but did not contain any medicine). To confirm the results, researchers have started a larger study, called TrilynX, that will compare the same treatments in around 700 people worldwide. This study will show if adding xevinapant to chemoradiotherapy can help to keep the cancer from progressing, control symptoms better and help people live longer. Clinical trial registration: NCT04459715 (ClinicalTrials.gov).
科研通智能强力驱动
Strongly Powered by AbleSci AI